118 related articles for article (PubMed ID: 31313703)
1. TRANSIENT PARADOXICAL WORSENING OF VISION DUE TO GRAVITATIONAL SHIFT OF SUBRETINAL FLUID AFTER PHOTODYNAMIC THERAPY FOR CENTRAL SEROUS CHORIORETINOPATHY.
Saengsirinavin AO; Ma D; Stewart JM
Retin Cases Brief Rep; 2021 Nov; 15(6):676-681. PubMed ID: 31313703
[TBL] [Abstract][Full Text] [Related]
2. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
Gulkas S; Sahin O
Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of photoreceptor loss and recovery after half-fluence photodynamic therapy for chronic central serous chorioretinopathy.
Gutiérrez-Hernández JC; Martínez-Camarillo JC; Sadda SR
Retin Cases Brief Rep; 2015; 9(2):109-13. PubMed ID: 25383847
[TBL] [Abstract][Full Text] [Related]
4. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
5. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.
Zhao M; Zhang F; Chen Y; Dai H; Qu J; Dong C; Kang X; Liu Y; Yang L; Li Y; Zhou P; Pan CT; Zhang L; Liu P; Zhou H; Jiao X; Xiong Y; Tian R; Lu Y; Yu X; Li X
JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191
[TBL] [Abstract][Full Text] [Related]
6. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
Matušková V; Vysloužilová D; Uher M
Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
[TBL] [Abstract][Full Text] [Related]
7. Half-fluence photodynamic therapy in acute central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Moussa S; Glittenberg C; Krebs I; Binder S
Retina; 2012; 32(10):2014-9. PubMed ID: 22466482
[TBL] [Abstract][Full Text] [Related]
8. ATYPICAL CENTRAL SEROUS CHORIORETINOPATHY WITH CHOROIDAL DETACHMENT: A CASE REPORT.
Manayath GJ; Kuthirummal N; Ranjan R; Verghese S; Venkatapathy N
Retin Cases Brief Rep; 2022 Nov; 16(6):735-739. PubMed ID: 33017379
[TBL] [Abstract][Full Text] [Related]
9. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
[TBL] [Abstract][Full Text] [Related]
10. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.
Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF;
Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758
[TBL] [Abstract][Full Text] [Related]
11. [Photodynamic therapy for treatment of chronic or recurrent central serous chorioretinopathy].
Li L; Yuan F; Xu GZ; Wang WJ
Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):106-13. PubMed ID: 22490944
[TBL] [Abstract][Full Text] [Related]
12. COMPARISON OF HALVING THE IRRADIATION TIME OR THE VERTEPORFIN DOSE IN PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Shiode Y; Morizane Y; Kimura S; Hosokawa M; Kawata T; Doi S; Hosogi M; Fujiwara A; Shiraga F
Retina; 2015 Dec; 35(12):2498-504. PubMed ID: 26035398
[TBL] [Abstract][Full Text] [Related]
13. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
Nicolò M; Zoli D; Musolino M; Traverso CE
Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
[TBL] [Abstract][Full Text] [Related]
14. BACILLARY LAYER DETACHMENT AFTER PHOTODYNAMIC THERAPY FOR CENTRAL SEROUS CHORIORETINOPATHY.
Ledesma-Gil G; Desmettre T; Mainster MA
Retin Cases Brief Rep; 2023 May; 17(3):239-241. PubMed ID: 34580248
[TBL] [Abstract][Full Text] [Related]
15. Atypical transient subretinal exudation following photodynamic therapy for chronic central serous retinopathy: a case report.
Al-Awadi A; Mandelcorn ED; Somani S
Can J Ophthalmol; 2017 Feb; 52(1):e38-e41. PubMed ID: 28237171
[No Abstract] [Full Text] [Related]
16. Retinal sensitivity after selective retina therapy (SRT) on patients with central serous chorioretinopathy.
Yasui A; Yamamoto M; Hirayama K; Shiraki K; Theisen-Kunde D; Brinkmann R; Miura Y; Kohno T
Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):243-254. PubMed ID: 27497611
[TBL] [Abstract][Full Text] [Related]
17. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Son BK; Kim K; Kim ES; Yu SY
Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
[TBL] [Abstract][Full Text] [Related]
19. Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-naïve central serous chorioretinopathy.
Li M; Qu J; Liang Z; Tang J; Hu J; Yao Y; Jin E; Li X; Zhao M
Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2175-2182. PubMed ID: 35024912
[TBL] [Abstract][Full Text] [Related]
20. Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence.
Park W; Kim M; Kim RY; Park YH
Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2155-2161. PubMed ID: 31367848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
